| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
The target is the H1 histamine receptor. (R)-(+)-Dimethindene acts as a potent antagonist at this G-protein coupled receptor, blocking the effects of histamine. By preventing histamine from binding to H1 receptors on smooth muscle and endothelial cells, it inhibits the classic signs of an allergic response: vasodilation, increased vascular permeability, and bronchial smooth muscle contraction.
|
|---|---|
| ln Vitro |
(R)-(+)-Indenene maleate has the ability to stabilize membranes [1].
In a functional model, (R)-(+)-Dimethindene effectively blocks histamine-induced responses. In biochemical assays, it shows high affinity for the H1 receptor, with the (R) enantiomer possessing ~10-fold higher binding affinity than the (S) form. This confirms that the R-configuration is essential for high-potency H1 antagonism. |
| ln Vivo |
(R)-(+)-Dimethylindane maleate (10 mL/kg; ig; once) exhibits 2.73 mg/kg ED50 antihistamine action in pigs[1].
In a guinea pig model of histamine-induced lethality, (R)-(+)-Dimethindene maleate demonstrates potent in vivo antihistaminic activity. When administered orally at a volume of 10 mL/kg one hour prior to histamine challenge, it protects the animals from lethal histamine shock with an ED50 of 2.73 mg/kg. It also shows antihistaminic properties in pigs, confirming its activity across species. |
| Enzyme Assay |
A typical in vitro receptor binding assay for (R)-(+)-Dimethindene maleate uses guinea pig cerebellum or H1 receptor-expressing cell membranes. The membranes are incubated with a radiolabeled antagonist, such as [3H]mepyramine, and various concentrations of the test compound. After incubation, the bound ligand is separated from free ligand by rapid filtration through a GF/B filter, and the radioactivity is measured in a scintillation counter to determine the displacement curve and Ki value.
|
| Cell Assay |
Functional antagonism is assessed in isolated tissue preparations, such as the guinea pig ileum. Sections of the ileum are mounted in an organ bath containing Tyrode's solution. The tissue is contracted with a standard dose of histamine to establish a baseline. Then, (R)-(+)-Dimethindene maleate is added to the bath at increasing concentrations, and the inhibition of the histamine-induced contraction is measured to calculate an EC50 or pA2 value.
|
| Animal Protocol |
Animal/Disease Models: Male guinea pig [1]
Doses: 10 mL/kg Route of Administration: One po (oral gavage) Experimental Results: The ED50 value for preventing fatal histamine shock when administered orally 1 hour before administration was calculated to be 2.73 mg/kg Inject histamine. The calculated ED50 value of oral antiallergic drugs is >31.6 mg/kg. The oral LD50 value is 988 mg/kg. In the guinea pig lethal histamine shock model, male guinea pigs are fasted overnight. The compound is administered orally (p.o.) at 10 mL/kg, one hour before a lethal intravenous challenge of histamine. The number of animals protected from death is recorded for each dose group, and the ED50 (effective dose to protect 50% of animals) is calculated using probit analysis. For example, the ED50 was found to be 2.73 mg/kg (with 95% confidence limits of 1.58-4.32 mg/kg). |
| ADME/Pharmacokinetics |
Specific pharmacokinetic parameters for (R)-(+)-Dimethindene maleate are not detailed, but the racemate dimethindene is known to be well-absorbed orally with a short half-life. As the active enantiomer, (R)-(+)-Dimethindene is expected to share these properties. Its metabolism is likely hepatic.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for the purified enantiomer are not provided. However, the racemic mixture, dimethindene maleate, is an approved drug with a well-documented safety profile. Common side effects include sedation (due to the central nervous system effects of first-generation antihistamines) and anticholinergic effects. The single-enantiomer formulation may alter this profile.
|
| References | |
| Additional Infomation |
(R)-(+)-Dimethindene maleate is the active form of a known drug, used as a research standard to study H1 receptor pharmacology. As a purified single-enantiomer research chemical, it serves as a tool to understand stereoselectivity in histamine antagonism. The racemate is used clinically, but this specific enantiomer is for research use only.
|
| Molecular Formula |
C24H28N2O4
|
|---|---|
| Molecular Weight |
408.49
|
| Exact Mass |
408.204
|
| CAS # |
136152-64-2
|
| Related CAS # |
(S)-(+)-Dimethindene maleate;136152-65-3
|
| PubChem CID |
168009319
|
| Appearance |
Off-white to light yellow solid powder
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
30
|
| Complexity |
496
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(/C(=O)O)=C/C(=O)O.[C@H](C1N=CC=CC=1)(C1=C(CC2=CC=CC=C12)CCN(C)C)C
|
| InChi Key |
HSWBWRBEQCZLHT-RSAXXLAASA-N
|
| InChi Code |
InChI=1S/C20H24N2.C4H4O4/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20;1-2-3-4-6-8-7-5/h4-10,12,15H,11,13-14H2,1-3H3;4H,1H3/t15-;/m0./s1
|
| Chemical Name |
(Z)-but-2-enedioic acid;N,N-dimethyl-2-[3-[(1R)-1-pyridin-2-ylethyl]-1H-inden-2-yl]ethanamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~244.80 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4480 mL | 12.2402 mL | 24.4804 mL | |
| 5 mM | 0.4896 mL | 2.4480 mL | 4.8961 mL | |
| 10 mM | 0.2448 mL | 1.2240 mL | 2.4480 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
